High dose pyridoxine as an 'anti-stress' strategy

Medical Hypotheses

Volumn 54, Issue 5, 2000, Pages 803-807

  McCarty, M F ^a  

^a Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CARBOXYLYASE; CORTICOSTEROID; GLUCOCORTICOID RECEPTOR; HOMOCYSTEINE; NEUROTRANSMITTER; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; SEROTONIN;

ANTIHYPERTENSIVE ACTIVITY; ANXIETY NEUROSIS; DEPRESSION; DYSPHORIA; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NOCICEPTION; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STRESS; SYMPATHETIC NERVE;

ANIMALIA; RODENTIA;

EID: 0034112282     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0955     Document Type: Article

References (70)

1. Ellis J. M., McCully K. S. Prevention of myocardial infarction by vitamin B6. Res Commun Mol Pathol Pharmacol. 89:1995;208-220.
2. Rimm E. B., Willett W. C., Hu F. B. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women [see comments]. JAMA. 279:1998;359-364.
3. Chasan-Taber L., Selhub J., Rosenberg I. H. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr. 15:1996;136-143.
4. Dalery K., Lussier-Cacan S., Selhub J., Davignon J., Latour Y., Genest J. J. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate. Am J Cardiol. 75:1995;1107-1111.
5. Kok F. J., Schrijver J., Hofman A., Witteman J. C., Kruyssen D. A., Remme W. J. Low vitamin B6 status in patients with acute myocardial infarction. Am J Cardiol. 63:1989;513-516.
6. Serfontein W. J., Ubbink J. B., De Villiers L. S., Rapley C. H., Becker P. J. Plasma pyridoxal-5-phosphate level as risk index for coronary artery disease. Atherosclerosis. 55:1985;357-361.
7. Folsom A. R., Nieto F. J., McGovern P. G. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the atherosclerosis risk in communities (ARIC) study [see comments]. Circulation. 98:1998;204-210.
8. Robinson K., Mayer E. L., Miller D. P. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation. 92:1995;2825-2830.
9. Robinson K., Arheart K., Refsum H. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group [see comments]. Circulation. 97:1998;437-443.
10. Keniston R. C., Enriquez J. I. S., Delgado I. Prognostic value of serum albumin and undeproteinized plasma pyridoxal 5′-phosphate [letter; comment]. Am J Clin Nutr. 49:1989;1328-1329.
11. Keniston R. C., Enriquez J. I. S., Delgado I. Prognostic value of undeproteinized plasma pyridoxal 5′-phosphate levels in health and disease. Ann NY Acad Sci. 585:1990;496-498.
12. Lipson M. H., Kraus J., Rosenberg L. E. Affinity of cystathionine beta-synthase for pyridoxal 5′-phosphate in cultured cells. A mechanism for pyridoxine-responsive homocystinuria. J Clin Invest. 66:1980;188-193.
13. Ornish, D. Love and Survival. New York, HarperCollins, 1997.
14. Ornish D., Scherwitz L. W., Billings J. H. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 280:1998;2001-2007.
15. Bjorntorp P. Stress and cardiovascular disease. Acta Physiol Scand Suppl. 640:1997;144-148.
16. Bjorntorp P. Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? J Intern Med. 230:1991;195-201.
17. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J. 19:1998;F14-F18.
18. Skantze H. B., Kaplan J., Pettersson K. Psychosocial stress causes endothelial injury in cynomolgus monkeys via beta l-adrenoceptor activation. Atherosclerosis. 136:1998;153-161.
19. Williams J. K., Kaplan J. R., Manuck S. B. Effects of psychosocial stress on endothelium-mediated dilation of atherosclerotic arteries in cynomolgus monkeys. J Clin Invest. 92:1993;1819-1823.
20. Rosenman R. H. Results of the multicenter antihypertensive treatment trials. Therapeutic implications and the role of the sympathetic nervous system. Am J Hypertens. 2:1989;313S-338S.
21. Weber M. A. Sympathetic nervous system and hypertension. Therapeutic perspectives. Am J Hypertens. 2:1989;147S-152S.
22. Muller J. E., Tofler G. H., Willich S. N., Stone P. H. Circadian variation of cardiovascular disease and sympathetic activity. J Cardiovasc Pharmacol. 10:1987;S104-S109.
23. Kennedy H. L. Beta blockade, ventricular arrhythmias, and sudden cardiac death. Am J Cardiol. 80:1997;29J-34J.
24. Behrens S., Ehlers C., Bruggemann T. Modification of the circadian pattern of ventricular tachyarrhythmias by beta-blocker therapy. Clin Cardiol. 20:1997;253-257.
25. Jayo J. M., Shively C. A., Kaplan J. R., Manuck S. B. Effects of exercise and stress on body fat distribution in male cynomolgus monkeys. Int J Obes Relat Metab Disord. 17:1993;597-604.
26. Kelly J. J., Mangos G., Williamson P. M., Whitworth J. A. Cortisol and hypertension. Clin Exp Pharmacol Physiol Suppl. 25:1998;S51-S56.
27. Kelly J. J., Tam S. H., Williamson P. M., Lawson J., Whitworth J. A. The nitric oxide system and cortisol-induced hypertension in humans. Clin Exp Pharmacol Physiol. 25:1998;945-946.
28. Dakshinamurti K., Sharma S. K., Bonke D. Influence of B vitamins on binding properties of serotonin receptors in the CNS of rats. Klin Wochenschr. 68:1990;142-145.
29. Hartvig P., Lindner K. J., Bjurling P., Laengstrom B., Tedroff J. Pyridoxine effect on synthesis rate of serotonin in the monkey brain measured with positron emission tomography. J Neural Transm Gen Sect. 102:1995;91-97.
30. Paulose C. S., Dakshinamurti K., Packer S., Stephens N. L. Sympathetic stimulation and hypertension in the pyridoxine-deficient adult rat. Hypertension. 11:1988;387-391.
31. Dakshinamurti K., Paulose C. S., Viswanathan M., Siow Y. L. Neuroendocrinology of pyridoxine deficiency. Neurosci Biobehav Rev. 12:1988;189-193.
32. Kleijnen J., Ter Riet G., Knipschild P. Vitamin B6 in the treatment of the premenstrual syndrome - a review [published erratum appears in Br J Obstet Gynaecol 1991 Mar; 98(3): 329-30] [see comments]. Br J Obstet Gynaecol. 97:1990;847-852.
33. Bernstein A. L. Vitamin B6 in clinical neurology. Ann N Y Acad Sci. 585:1990;250-260.
34. Doll H., Brown S., Thurston A., Vessey M. Pyridoxine (vitamin B6) and the premenstrual syndrome: a randomized crossover trial. J R Coll Gen Pract. 39:1989;364-368.
35. Brush M. G., Bennett T., Hansen K. Pyridoxine in the treatment of premenstrual syndrome: a retrospective survey in 630 patients. Br J Clin Pract. 42:1988;448-452.
36. Bermond P. Therapy of side effects of oral contraceptive agents with vitamin B6. Acta Vitaminol Enzymol. 4:1982;45-54.
37. Fu Q. G., Carstens E., Stelzer B., Zimmermann M. B vitamins suppress spinal dorsal horn nociceptive neurons in the cat. Neurosci Lett. 95:1988;192-197.
38. Bernstein A. L., Dinesen J. S. Brief communication: effect of pharmacologic doses of vitamin B6 on carpal tunnel syndrome, electroencephalographic results, and pain. J Am Coll Nutr. 12:1993;73-76.
39. Bartoszyk G. D., Wild A. Antinociceptive effects of pyridoxine, thiamine and cyanocobalamin in rats. Ann N Y Acad Sci. 585:1990;473-476.
40. Baldewicz T., Goodkin K., Feaster D. J. Plasma pyridoxine deficiency is related to increased psychological distress in recently bereaved homosexual men. Psychosom Med. 60:1998;297-308.
41. Dakshinamurti K., Paulose C. S., Viswanathan M. Vitamin B6 and hypertension. Ann N Y Acad Sci. 585:1990;241-249.
42. Lal K. J., Dakshinamurti K., Thliveris J. The effect of vitamin B6 on the systolic blood pressure of rats in various animal models of hypertension. J Hypertens. 14:1996;355-363.
43. Fregly M. J., Cade J. R. Effect of pyridoxine and tryptophan, alone and combined, on the development of deoxycorticosterone acetate-induced hypertension in rats. Pharmacology. 50:1995;298-306.
44. Lal K. J., Dakshinamurti K. Calcium channels in vitamin B6 deficiency-induced hypertension. J Hypertens. 11:1993;1357-1362.
45. Dakshinamurti K., Lal K. J. Vitamins and hypertension. World Rev Nutr Diet. 69:1992;40-73.
46. Viswanathan M., Bose R., Dakshinamurti K. Increased calcium influx in caudal artery of rats made hypertensive with pyridoxine deficiency. Am J Hypertens. 4:1991;252-255.
47. Aybak M., Sermet A., Ayyildiz M. O., Karakilcik A. Z. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Arzneimittelforschung. 45:1995;1271-1273.
48. Fregly M. J. Effects of tryptophan on the development of deoxycorticosterone acetate (DOCA)-induced hypertension in rats. Adv Exp Med Biol. 294:1991;619-623.
49. Baron A., Riesselmann A., Fregly M. J. Reduction in the elevated blood pressure of Dahl salt-sensitive rats treated chronically with L-5-hydroxytryptophan. Pharmacology. 42:1991;15-22.
50. Lark L. A., Becker K. B., Park R. E., Weyhenmeyer J. A. Prevention of Dahl salt-induced hypertension by chronic dietary tryptophan. Can J Physiol Pharmacol. 68:1990;1432-1436.
51. Fregly M. J., Sumners C., Cade J. R. Effect of chronic dietary treatment with L-tryptophan on the maintenance of hypertension in spontaneously hypertensive rats. Can J Physiol Pharmacol. 67:1989;656-662.
52. Itskovitz H. D., Werber J. L., Sheridan A. M., Brewer T. F., Stier C. T. J. 5-Hydroxytryptophan and carbidopa in spontaneously hypertensive rats. J Hypertens. 7:1989;311-315.
53. Oka T., Komori N., Kuwahata M. Pyridoxal 5′-phosphate modulates expression of cytosolic aspartate aminotransferase gene by inactivation of glucocorticoid receptor. J Nutr Sci Vitaminol (Tokyo). 41:1995;363-375.
54. Tully D. B., Allgood V. E., Cidlowski J. A. Modulation of steroid receptor-mediated gene expression by vitamin B6. FASEB J. 8:1994;343-349.
55. Allgood V. E., Powell-Oliver F. E., Cidlowski J. A. Vitamin B6 influences glucocorticoid receptor-dependent gene expression. J Biol Chem. 265:1990;12424-12433.
56. Allgood V. E., Powell-Oliver F. E., Cidlowski J. A. The influence of vitamin B6 on the structure and function of the glucocorticoid receptor. Ann N Y Acad Sci. 585:1990;452-465.
57. Maksymowych A. B., Daniel V., Litwack G. Pyridoxal phosphate as a regulator of the glucocorticoid receptor. Ann N Y Acad Sci. 585:1990;438-451.
58. Compton M. M., Cidlowski J. A. Vitamin B6 and glucocorticoid action. Endocrinol Rev. 7:1986;140-148.
59. Yoneda T., Pratt R. M. Vitamin B6 reduces cortisone-induced cleft palate in the mouse. Teratology. 26:1982;255-258.
60. Lettko M., Meuer S. Vitamin B-induced prevention of stress-related immunosuppression. Ann N Y Acad Sci. 585:1990;513-515.
61. Lindenbaum E. S., Mueller J. J. Effects of pyridoxine on mice after immobilization stress. Nutr Metab. 17:1974;368-374.
62. Walker B. R., Phillips D. I., Noon J. P., Panarelli M., Andrew R., Edwards H. V. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension. 31:1998;891-895.
63. Walker B. R. Abnormal glucocorticoid activity in subjects with risk factors for cardiovascular disease. Endocrinol Res. 22:1996;701-708.
64. Ellis, J. M. Pamplin, J. Vitamin B6 Therapy. New York, Avery, 1999.
65. Bendich A., Cohen M. Vitamin B6 safety issues. Ann N Y Acad Sci. 585:1990;321-330.
66. Horrobin D. F. Loss of delta-6-desaturase activity as a key factor in aging. Med Hypotheses. 7:1981;1211-1220.
67. Ellis J. M., Folkers K., Minadeo M., VanBuskirk R., Xia L. J., Tamagawa H. A deficiency of vitamin B6 is a plausible molecular basis of the retinopathy of patients with diabetes mellitus. Biochem Biophys Res Commun. 179:1991;615-619.
68. Solomon L. R., Cohen K. Erythrocyte O2 transport and metabolism and effects of vitamin B6 therapy in type II diabetes mellitus. Diabetes. 38:1989;881-886.
69. Hayakawa M., Shibata M. The in vitro and in vivo inhibition of protein glycosylation and diabetic vascular basement membrane thickening by pyridoxal-5′-phosphate. J Nutr Sci Vitaminol (Tokyo). 37:1991;149-159.
70. Khatami M. Role of pyridoxal phosphate/pyridoxine in diabetes: inhibition of nonenzymatic glycosylation. Ann N Y Acad Sci. 585:1990;502-504.